Luxturna acts by delivering a subretinal injection of a functional copy of RPE65 packaged in an adeno-associated viral (AAV) vector to supplement the two mutant copies of RPE65 present in LCA patients [29]. Here, RPE65 is linked to Leber congenital amaurosis.